Please assess the completion status of the following clinical trial:

Trial Title: Contrast-enhanced Ultrasound Evaluation of Chemoembolization

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients \>= 21 years of age~* Patient capable of making informed decisions regarding his/her treatment~* Scheduled for TACE treatment of a HCC mass (lesions reported as Liver Imaging Reporting and Data Systems 4B or 5 or Organ Procurement and Transplantation Network 5a or 5b)~* Negative pregnancy test in a female of child-bearing age.~* Have an HCC mass viewable on grayscale B-mode ultrasound.~Exclusion Criteria:~* Females who are pregnant or nursing.~* Patients not eligible or scheduled for TACE of a HCC mass.~* Patients who have received an investigational drug in the 30 days before study drug administration, or will receive one within 72 h after their final CEUS exam.~* Patients who have received prior radioembolization (Y90) of the lesion of interest.~* Patients with known or suspected cardiac shunts.~* Patients with pulmonary hypertension or unstable cardiopulmonary conditions.~* Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable. For example:~* Patients with unstable occlusive disease (e.g., crescendo angina)~* Patients with clinically unstable cardiac arrhythmias~* Patients with uncontrolled congestive heart failure (NYHA Class IV)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Contrast ultrasound arm (Type: EXPERIMENTAL): Patients receiving contrast-enhanced ultrasound for diagnosis of chemoembolization response.

Based on this trial design, predict the completion outcome and termination type (if applicable).